Meet us at CPHI Milan 2026, Booth No. 10H33, Oct 6-8, Fiera Milano, Italy Schedule a Meeting
De-risk scale-up, impurity, and manufacturing challenges with a trusted CDMO partner supporting your molecule from development through commercial supply.
As a leading pharmaceutical CDMO, Neuland provides integrated CDMO services across the drug development lifecycle for complex small molecules and peptides. From early-stage development to clinical trial material manufacturing and commercial API manufacturing, we combine deep chemistry expertise with scalable infrastructure to help you advance molecules with confidence.
Our contract development and manufacturing capabilities span early development, scale-up, and commercial production, helping you transition seamlessly across each phase with reduced technical and operational risk.
Enabling Complex Chemistry at Scale
Deep expertise in synthetic chemistry and new chemical entities (NCEs), supporting complex reaction pathways and process scale-up, and reliable commercial API manufacturing; helping you advance challenging molecules efficiently to commercial production.
Specialized Synthesis of Complex and High-Purity Peptides
Advanced capabilities in custom peptide synthesis, including SPPS, LPPS, and hybrid approaches enabling high-purity, sequence-specific peptides with reduced scale-up risk and supporting a seamless path to consistent commercial supply.
In a complex chiral intermediate manufacturing program, Neuland transformed a difficult asymmetric hydrogenation process into a robust, scalable commercial-ready operation. By optimizing catalyst efficiency, enhancing process safety, and ensuring stringent control of critical reaction parameters, the team achieved successful scale-up to 100 kg while consistently delivering exceptional purity (99%), enantioselectivity (99%), and yield (85%).
Our scientists bring deep expertise in complex chemistry and scalable manufacturing. Start a conversation to explore how our drug development CDMO capabilities can support your molecule from early development through commercial supply.
Quick answers to help you better understand our CDMO capabilities and approach.
Still have Questions? Contact UsYou can engage a CDMO as early as preclinical or IND-stage development. Early engagement helps optimize process design, reduce scale-up risks, and align development with regulatory expectations.
For programs already in clinical stages, a CDMO can support process optimization, tech transfer, and seamless progression to commercial supply.
Yes. A CDMO partner can assess, optimize, and transfer existing processes across development stages. This includes evaluating process robustness, impurity profiles, and scalability to ensure readiness for clinical or commercial manufacturing.
Well-managed tech transfer minimizes disruption and ensures continuity across stages.
Scale-up risk is addressed through structured process development, pilot-scale validation, and controlled technology transfer.
Key focus areas include: Process robustness and reproducibility, impurity control and yield optimization, and alignment between development and manufacturing teams to reduce late-stage failures and ensure smoother transition into commercial production.
A CDMO supports preparation of CMC documentation required for IND, NDA, and global submissions, including process descriptions, analytical data, and validation reports.
They also assist in regulatory query responses, inspection readiness, and post-approval changes and lifecycle management.
Yes, an integrated API CDMO can support programs from development through commercial API manufacturing, reducing tech transfer complexity and ensuring continuity across the lifecycle.
This reduces tech transfer complexity, timeline delays, and coordination gaps between multiple vendors, while ensuring continuity in process knowledge, documentation, and quality systems across the lifecycle.
